1.0Alcanza Clinical Researchhttps://alcanzaclinical.com/esSarah Belanushttps://alcanzaclinical.com/es/author/sarahcellsignalmarketing-com/rich600338<blockquote class="wp-embedded-content" data-secret="i9Skl004CR"><a href="https://alcanzaclinical.com/es/5704-2/">Alcanza Doses First Patient in Novel Alzheimer’s Trial</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://alcanzaclinical.com/es/5704-2/embed/#?secret=i9Skl004CR" width="600" height="338" title="“Alcanza Doses First Patient in Novel Alzheimer’s Trial” — Alcanza Clinical Research" data-secret="i9Skl004CR" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://alcanzaclinical.com/wp-includes/js/wp-embed.min.js </script>https://alcanzaclinical.com/wp-content/uploads/2025/08/LinkedIn-Templates-9.png1200627The Alcanza team at NeuroStudies has successfully dosed the first patient in a first-in-human clinical trial for a novel antibody targeting Alzheimer’s Disease. Alcanza is honored to be selected as one of only three U.S. sites entrusted with this important milestone. The first patient enrolled was the first person globally, out of more than 8 […]